Yohimbina

Yohimbine

1. Identity: Botanical and Chemical Profile

1.1 Botanical Source and Taxonomy

Corynanthe johimbe, synonym Pausinystalia johimbe, common name yohimbe, is a plant species in the family Rubiaceae native to western and central Africa — specifically Nigeria, Cabinda, Cameroon, Congo-Brazzaville, Gabon, and Equatorial Guinea. In scientific papers generally, the usage Pausinystalia johimbe is the most frequent, followed by Pausinystalia yohimbe. The genus Pausinystalia belongs to the Rubiaceae; the principal species of medicinal interest is Pausinystalia yohimbe (K. Schum.) Pierre ex Beille, sometimes spelled as P. johimbe or P. yohimba. Another Latin binomial for this species is Corynanthe yohimbe K. Schum.

Yohimbe is one of a number of Corynanthe evergreen species growing in West and Central Africa in lowland forests. The tree grows about 30 m (98 ft) tall, with a straight bole that is rarely larger than 50–60 cm in diameter. The bark is grey to reddish-brown, with longitudinal fissures, easy to peel and bitter-tasting. The inner bark is pinkish and fibrous.

1.2 Chemical Identity of Yohimbine

Yohimbine — molecular formula C₂₁H₂₆N₂O₃ — is a naturally occurring indole alkaloid primarily derived from the bark of the Pausinystalia yohimbe tree, indigenous to West Africa. Its systematic chemical name is 17α-hydroxyyohimban-16α-carboxylic acid methyl ester. It has also been called quebrachine, aphrodine, corynine, and hydroaerogotocin.

Yohimbine, also known as quebrachine, is an indole alkaloid derived from the bark of the African tree Pausinystalia johimbe (yohimbe) and from the bark of the unrelated South American tree Aspidosperma quebracho-blanco. This alkaloid also occurs in Rauwolfia serpentina.

Yohimbine has two stereoisomers — rauwolscine and corynanthine — that differ little in their physical properties or in their effects on serotonin and dopamine receptors. The three isomers, however, do differ significantly in their affinity for the alpha-1 and alpha-2 adrenoceptor subtypes. The other alkaloid components of the bark are primarily yohimbine stereoisomers or derivatives thereof, and tannins.

1.3 Alkaloid Content and Phytochemistry

The yohimbine content in the bark is given as 7–115 mg/g and is usually around 10 mg/g, with values dependent largely on the method of analysis. The main stem gives the best material but is not rich in alkaloids until the tree is 15–20 years of age, by which time it can contain 2–15% yohimbine. Bark exploitation is a seasonal activity, as yohimbine levels are highest during the rainy season. The bark or bark extract of the yohimbe tree contains many chemical substances, and yohimbine is just one of 55 alkaloids that have been identified.

1.4 Common Forms and Preparations

Yohimbine also occurs in many other plants such as the quebracho blanco plant of South America. It can also be produced synthetically — made in a laboratory — as yohimbine hydrochloride. It is sold in capsule or tablet form and marketed as yohimbe bark extract or yohimbine (the active ingredient in yohimbe bark). Yohimbine is well soluble in alcohol and poorly soluble in water.

Yohimbine is clinically utilized as a prescription drug, with its main dosage forms in powder and tablets, and is also available for purchase on the internet as an herbal supplement and oral liquid. Dietary supplements containing yohimbe or yohimbine have been marketed to increase energy, improve body composition, support fat burning, and to enhance weight loss and sexual wellness.

2. Traditional and Historical Use

2.1 West African Ethnomedicinal Use

Extracts from yohimbe have been used in traditional medicine in West Africa as an aphrodisiac. Historically, yohimbe bark was used in western Africa for fevers, leprosy, and coughs. It has also been used to dilate pupils, for heart disease, and as a local anesthetic. It has a more recent history of use as an aphrodisiac and a hallucinogen.

Yohimbine has roots in traditional West African medicine, where the bark of the Pausinystalia yohimbe tree was used by indigenous tribes, including Pygmy communities, as an aphrodisiac to enhance sexual desire and performance for centuries.

2.2 Isolation and Early Scientific History

The alkaloid now known as yohimbine was first isolated in 1880 from the bark of the South American tree Aspidosperma quebracho-blanco by German chemist Otto Hesse, who named it quebrachine after its source. In 1896, German chemist Leopold Spiegel isolated the same alkaloid from yohimbe bark obtained from Cameroon, confirming its presence in the African tree and conducting initial chemical characterizations that highlighted its potential pharmacological activity. Spiegel's work linked the compound to ethnobotanical uses in African traditional medicine, where yohimbe bark was valued for its stimulant and aphrodisiac effects among local populations.

2.3 Conservation and Supply Chain Concerns

The tree is sought out primarily for its bark; in practice, harvesting the bark kills the tree. Tree density is relatively low (average approximately 4 harvestable trees per hectare). The high demand for medicines based on the bark has led to the tree's over-exploitation. The bark is traded in local markets and, because it is scarce, it is often adulterated with that of other species which contain little yohimbine. The species is becoming endangered. Around the year 2000, Cameroon was shipping P. johimbe to Europe at the rate of about 100 tonnes annually. Most bark is collected illegally by local people who are paid approximately US$0.10 per pound for delivery of pre-dried bark at the roadside. In practice they confuse and mix it with P. macroceras ("false yohimbe"), a species that contains little yohimbine.

3. Key Constituents and Mechanisms of Action

3.1 Primary Mechanism: Alpha-2 Adrenoceptor Antagonism

Yohimbine (YOH) is a potent selective α2-adrenoceptor antagonist with weaker α1-antagonist activity, as demonstrated by radioreceptor ligand binding assays and by pharmacological studies. Yohimbine works by blocking alpha-2 adrenergic receptors, protein molecules on nerve cells that are stimulated by norepinephrine. This results in increased blood flow into the penis and reduced outflow of blood, which helps maintain an erection.

Plasma norepinephrine concentrations are increased (40–50%) after oral yohimbine administration. The rise in plasma catecholamine concentration elicited by yohimbine was not modified by propranolol treatment. The lipid-mobilizing effect of yohimbine could be attributable to: (i) the increase in synaptic norepinephrine with a resultant increment in lipolysis by beta-adrenergic agonism; (ii) a decrease in alpha-2 adrenoceptor stimulation of human fat cell alpha-2 adrenoceptors; (iii) a blockade of presynaptic alpha-2 adrenoceptors.

3.2 Serotonergic and Dopaminergic Activity

Yohimbine enhances frontocortical levels of dopamine and noradrenaline, yet suppresses those of serotonin, the latter effect being antagonized by WAY100,635. Due to its ability to selectively block α2-adrenoceptors in the brain, yohimbine can increase the release of norepinephrine and dopamine and improve feelings, thus it is studied as a potential antidepressant.

3.3 MAO Inhibition

Yohimbine inhibits monoamine oxidase (MAO) and therefore may theoretically be of benefit in depressive disorders.

3.4 Lipolytic Mechanism

Alpha-2 antagonists including yohimbine, idazoxan, and SK&F-86,466 enhanced the lipolytic potencies of epinephrine, with an order of potency: yohimbine > idazoxan > SK&F-86,466; the same order was also found in [³H]-yohimbine competition studies on human fat cell membranes. The lipid-mobilizing action of yohimbine is understood to operate through blockade of inhibitory α2-adrenoceptors on adipocytes, thereby allowing catecholamine-driven lipolysis to proceed unopposed.

3.5 Pharmacokinetics

Yohimbine is absorbed relatively quickly after oral ingestion, with an absorption half-life of 7–11 minutes. Peak plasma concentrations are reached within 45–60 minutes. However, the amount of yohimbine that actually reaches systemic circulation varies greatly between individuals. Bioavailability ranges from 10% to 90%.

Yohimbine has a relatively short half-life of less than 1 hour, indicating rapid clearance from the plasma. The kidneys excrete yohimbine and its metabolites, with less than 1% of the administered dose found unchanged in the urine after 24 hours.

Fractional clearance calculations demonstrate the almost exclusive and complete elimination of yohimbine via CYP2D6-mediated 11-hydroxylation. Individuals with certain CYP2D6 genotypes may exhibit impaired metabolism, resulting in higher plasma concentrations and an increased risk of adverse effects. In a documented case series, even though all individuals were assumed to have taken the same dose of drug powder, toxicology analyses revealed yohimbine blood concentrations of 249–5631 ng/mL — a 22-fold difference. Pharmacokinetic modeling shows that a patient's CYP2D6 phenotype can explain the large differences observed in measured concentration after intake of the same yohimbine dose.

A study simultaneously quantified plasma concentrations of yohimbine, its metabolite, and paroxetine after oral administration of 5 mg yohimbine alone and in combination with a three-day intake of 20 mg paroxetine to a healthy individual, enabling investigation of yohimbine pharmacokinetics and its CYP2D6-dependent metabolization. This resulted in doubled maximum concentration, a tenfold increase in AUC, and fourfold prolonged elimination half-life.

4. Scientific Evidence by Area of Use

4.1 Erectile Dysfunction

The predominant use of yohimbine has been as a pharmacological tool to study the involvement of α2-adrenergic receptors in the regulation of autonomic function and for the treatment of impotence in males. Its action in this context is probably connected with the inhibition of the α2 adrenergic receptors in the corpus cavernosum.

A landmark meta-analysis by Ernst and Pittler (1998), encompassing the literature through 1997, remains the most frequently cited systematic review on this topic. The authors systematically reviewed and meta-analyzed all randomized, placebo-controlled trials of yohimbine monotherapy for erectile dysfunction to determine its therapeutic efficacy, with a secondary aim of evaluating safety. Using computerized literature searches and standardized data extraction, seven trials fit the predefined inclusion criteria. Overall methodological quality of these studies was satisfactory. The meta-analysis demonstrated that yohimbine is superior to placebo in the treatment of erectile dysfunction (odds ratio 3.85, 95% confidence interval 6.67 to 2.22). Serious adverse reactions were infrequent and reversible.

A more recent systematic review and meta-analysis (Wibowo et al.) included eight randomized controlled trials. Both yohimbine alone (odds ratio [OR] = 2.08, 95% CI 1.30–3.32, P = .002) and combined preparations (OR = 6.35, 95% CI 3.01–13.41, P < .001) showed a significantly greater probability of erectile function improvement compared to placebo. However, some studies suggested that the aphrodisiac effects of the extract were only a placebo effect or due to the increase in peripheral vascular congestion. In contrast, other studies reported that it could provide excellent curative effects on organic impotence.

In the constituent trials, yohimbine was administered orally at doses of 5 to 10 mg three times per day, or yohimbine hydrochloride at 5, 5.4 or 6 mg given 3, 4, or 8 times per day, for periods of 2 to 10 weeks.

Evidence strength: Moderate. Multiple RCTs and two meta-analyses support statistical superiority over placebo, particularly for psychogenic erectile dysfunction. Effect sizes are meaningful but not large, individual trial quality varies, and current clinical guidelines prioritize PDE5 inhibitors. The NCCIH states that there is not enough evidence to reach definite conclusions about yohimbe supplement effectiveness for conditions such as erectile dysfunction.

4.2 Body Composition and Fat Loss

Mechanistically, blockade of adipocyte α2-adrenoceptors is a plausible basis for lipolytic effects. Human evidence is, however, mixed. One study examined yohimbine for suitability in the treatment of obesity. Twenty female obese outpatients were subjected to a 3-week low-energy diet (1,000 kcal/day), after which they were randomly allocated in a double-blind protocol to two treatments: 10 subjects received 5 mg yohimbine orally 4 times a day and 10 received placebo for 3 weeks in addition to the same diet. Yohimbine significantly increased mean weight loss in patients on a low-energy diet: 3.55 ± 0.24 kg (yohimbine) vs. 2.21 ± 0.37 kg (placebo), P < 0.005.

In contrast, a double-blind comparative study found no significant benefit. A double-blind comparative study of the selective α2-antagonist yohimbine in human obesity enrolled 19 obese volunteers, randomly allocated to the yohimbine group (n=10, 18 mg yohimbine/day) or placebo group (n=9). All subjects were maintained on a hypocaloric diet (1,000 kcal/day) during the 8 weeks of the study. There was no difference between the two groups with respect to either body weight, blood pressure supine and erect, or heart rate during the different phases of the study.

In a study of elite athletes, twenty top-level male soccer players were allocated to yohimbine or placebo groups; subjects in the yohimbine group orally ingested tablets containing yohimbine at a dose of 20 mg per day in two equal doses for 21 days. There were no statistically significant changes in body mass and muscle mass within or between trials (p > 0.05) after the supplementation protocol. Percentage of body fat significantly decreased in the yohimbine group after the supplementation protocol (9.3 ± 1.1 vs. 7.1 ± 2.2%; p < 0.05). Furthermore, fat mass was significantly lower in the yohimbine versus placebo trial at post-supplementation assessment. There were no changes in exercise performance indicators.

The lipid-mobilizing action of yohimbine was reinforced during physical exercise, completely suppressed after a meal, and partially blocked by administration of propranolol. This finding is mechanistically important: fat mobilization may depend on a fasted, active metabolic state.

Evidence strength: Preliminary and mixed. The use of yohimbine has only inconsistently promoted increased weight loss in placebo-controlled studies in humans. The body of evidence is limited by small sample sizes, variable populations, and divergent outcomes. No large-scale, high-quality RCT establishing clinically meaningful weight loss has been published to date.

4.3 Athletic Performance

A study aimed to determine the effects of yohimbine supplementation on exercise performance in 20 male professional soccer players. Before and after the supplementation protocol (10 mg of yohimbine HCl twice a day for 21 days), each participant performed several tests including bench press, leg press, vertical jump, power test, and endurance shuttle run. No within- or between-trial changes were observed. The available data does not support yohimbine supplementation to improve athletic performance in elite soccer players.

Evidence strength: Weak. The effectiveness of yohimbine for athletic performance remains inconclusive. Available evidence does not support ergogenic benefit.

4.4 Psychiatric Applications: Depression Augmentation

Yohimbine from the African yohimbe tree affects the nervous system in a way that may complement fluvoxamine. One report studied depressed people who had not responded to fluvoxamine. When 5 mg of yohimbine was added three times each day, there was significant improvement. Some people required higher amounts of yohimbine before their depression improved. A separate case report documented a 50-year-old woman unresponsive to traditional antidepressant therapy who experienced a marked and persistent improvement in mood when yohimbine was added to bupropion therapy, though further research was noted as necessary to determine the significance of this finding.

Evidence strength: Very preliminary. Evidence consists of case reports and small observational studies. No adequately powered, replicated RCTs have been conducted specifically for depressive disorders. Yohimbine's role as a pharmacological probe for noradrenergic activity is well-established, but therapeutic application in depression remains exploratory.

4.5 Anxiety Disorders: Augmentation of Exposure Therapy

Pathological fear and anxiety are highly debilitating and, despite considerable advances in psychotherapy and pharmacotherapy, they remain insufficiently treated in many patients. Increasing preclinical and clinical evidence indicates that pharmacological treatments including cognitive enhancers, when given as adjuncts to psychotherapeutic approaches such as extinction-based exposure therapy, can enhance treatment efficacy.

A randomized controlled trial enrolled adults (n = 40) with a DSM-IV diagnosis of social anxiety disorder, randomized to placebo or yohimbine HCl (10.8 mg) 1 hour before each of four exposure sessions. Outcome measures were collected at baseline, each treatment session, post-treatment, and 1-month follow-up. Yohimbine was well tolerated. Yohimbine augmentation, relative to placebo augmentation, resulted in faster improvement and better outcomes on self-report measures of social anxiety disorder severity (Liebowitz Social Anxiety Scale, d = .53) and depressed mood severity (Beck Depression Inventory, d = .37), but not on the clinician-rated measures.

The results provide moderate support for yohimbine as a therapeutic augmentation strategy for exposure therapy in social anxiety disorder, one that may be especially effective when coupled with successful exposure experiences.

However, not all studies agree. A randomized controlled trial showed that 10 mg of yohimbine increases norepinephrine levels but does not augment exposure therapy for fear of flying in 67 adults. A similar trial targeting specific phobias in 56 individuals found that yohimbine 15 mg did not augment therapy but was safe.

Importantly, yohimbine induces mild anxiety and increases impulsivity in healthy volunteers, but has more detrimental effects in some psychiatric populations, triggering mania in bipolar patients and drug-craving in substance-dependent individuals. Understanding the mechanism by which yohimbine affects brain function could provide insight into the heightened reaction to stress seen in these patients.

Evidence strength: Preliminary and inconsistent. A small RCT (n=40) showed moderate benefit for social anxiety disorder augmentation; other RCTs in different phobia populations did not replicate this finding. The overall evidence base is insufficient for clinical recommendations.

4.6 Orthostatic Hypotension

Yohimbine has been proposed for the treatment of neurogenic orthostatic hypotension; however, no controlled trial has been performed in experimental models of orthostatic hypotension or in patients with autonomic failure. Preclinical animal model data suggest a role for yohimbine's sympathomimetic mechanism in delaying pressure drops on postural change, but robust clinical evidence in humans is lacking.

4.7 Use as a Pharmacological Research Tool

Tritiated yohimbine ([³H]-yohimbine) was one of the first radioligands developed for selectively labeling alpha-2 adrenoceptors. In research settings, yohimbine's well-characterized α2 antagonism has made it a standard probe for studying noradrenergic function, autonomic physiology, anxiety neurobiology, and metabolic pharmacology. Its use as a pharmacological stressor in clinical studies — used to provoke noradrenergic challenge — is well-established in the psychiatric literature.

5. Body Systems and Health Areas

• Reproductive/Sexual System: The most well-known and widespread use of yohimbine is related to relieving erectile dysfunction and improving sexual stimulation. This is probably connected with the inhibition of the α2 adrenergic receptors in the corpus cavernosum.
• Autonomic Nervous System / Cardiovascular System: Yohimbine is a potent selective α2-adrenoceptor antagonist, resulting in increased central and peripheral sympathetic activity. It raises blood pressure and heart rate in a dose-dependent fashion and has been investigated for orthostatic hypotension.
• Metabolic / Adipose Tissue: Yohimbine has been shown to induce fat loss and, due to its presumed lipolytic properties, it is used for weight loss and bodybuilding. Human evidence is inconsistent.
• Central Nervous System / Psychiatric: Due to its ability to selectively block α2-adrenoceptors in the brain, yohimbine can increase the release of norepinephrine and dopamine and improve feelings, and it is studied as a potential antidepressant. It also functions as a pharmacological stressor and has been investigated as an augmentation agent for exposure therapy.
• Platelet Function: The effect of the selective α2-adrenergic receptor antagonist yohimbine on platelet aggregation has been evaluated in healthy subjects. Yohimbine administered orally selectively antagonized epinephrine-induced ex vivo platelet aggregation.

6. Dosage Forms and Dosages Reported in Studies

The following dosages reflect those reported in the cited primary and secondary literature. They are not recommendations.

• For erectile dysfunction trials: yohimbine 5 to 10 mg orally, 3 times per day; or yohimbine hydrochloride 5, 5.4, or 6 mg given 3, 4, or 8 times per day; for periods of 2 to 10 weeks.
• For weight loss (female obese outpatients, double-blind): 5 mg yohimbine per os, 4 times per day (total 20 mg/day), for 3 weeks combined with a 1,000 kcal/day diet.
• For obesity (double-blind, 8 weeks): 18 mg yohimbine/day combined with a 1,000 kcal/day hypocaloric diet.
• For body composition in soccer players: 20 mg per day in two equal doses (10 mg twice daily) for 21 days.
• For exposure therapy augmentation in social anxiety disorder: yohimbine HCl 10.8 mg administered 1 hour before each of four exposure therapy sessions.
• For noradrenergic research studies: a 10 mg single dose of yohimbine was used to increase noradrenergic activity.
• For antidepressant augmentation of fluvoxamine non-responders: 5 mg of yohimbine three times each day.
• In a platelet aggregation study: the lowest dose of yohimbine that significantly inhibited epinephrine-induced platelet aggregation was 8 mg.
• In a cerebrovascular study: 22 mg yohimbine hydrochloride in a randomized, double-masked, placebo-controlled trial in 14 healthy male volunteers.

7. Safety: Adverse Effects, Toxicology, and Drug Interactions

7.1 Documented Adverse Events

Adverse events following consumption of yohimbine include tachycardia (high heart rate), hypertension (high blood pressure), flushing, sweating, nausea, headaches, anxiety, and restlessness. The adverse effects of yohimbine include gastrointestinal distress, hypertension, tachycardia, manic reactions, bronchospasm, palpitations, insomnia/anxiety, chills/cold/shivering, sweating, flushing, and headaches, which can be attributed to its central adrenergic activity.

A retrospective review of the California Poison Control System covering a 7-year period (2000–2006) identified 238 cases of yohimbine-associated adverse drug events (ADEs). There was a substantial increase in the annual prevalence of yohimbine-associated ADEs reported between 2000 and 2006. Common reasons for use included sexual enhancement (27.7%), weight loss (9.2%), and stimulant effects (7.6%). Common ADEs reported included: gastrointestinal distress (46%), tachycardia (43%), anxiety/agitation (33%), and hypertension (25%). Yohimbine exposures were associated with a significantly greater proportion of severe outcomes and were more likely to require management at a health-care facility than the average substance exposure (odds ratios [95% CIs] were 5.81 [4.43 to 7.64] and 2.35 [1.82 to 3.04], respectively).

7.2 Serious and Severe Events

Yohimbine, a component of yohimbe, has been associated with cardiac arrhythmia (irregular heartbeat), blood pressure problems, heart attacks, and seizures. Common documented adverse events included GI distress, tachycardia, anxiety, hypertension, flushing/erythema, diaphoresis, tremor, and chest pain. Severe adverse drug events constituted myocardial infarctions, atrial fibrillation, QTc prolongation, seizures, acute renal failure, and priapism. In 2007, the American Association of Poison Control Centers' National Poison Data System disclosed that 60 yohimbine exposures out of the 277 reported had mounted to causing moderate to severe harm.

7.3 Psychiatric Vulnerabilities

The response to yohimbine is more pronounced and detrimental in some psychiatric populations: it can induce the transition to mania in bipolar disorder, trigger withdrawal symptoms and craving in opioid-dependent patients, and exacerbate panic and other symptoms in PTSD patients. Such data suggest that a hypersensitivity to norepinephrine may contribute to these psychopathologies. Individuals who experience anxiety, depression, hypertension, hypotension, or PTSD should avoid use of yohimbine.

7.4 Drug Interactions

Yohimbe should not be used if a person is taking types of antidepressant medications called monoamine oxidase inhibitors (MAOIs) or tricyclic antidepressants. Yohimbe can interact with these medications. This interaction is mechanistically consistent with yohimbine's own MAO-inhibitory activity and its enhancement of central noradrenergic tone.

Yohimbine, in combination with other stimulants such as caffeine, rauwolscine, ephedrine, and synephrine, can increase heart rate and pose cardiovascular risk.

Co-administration with the CYP2D6 inhibitor paroxetine (20 mg for three days) following 5 mg yohimbine resulted in doubled maximum plasma concentration, a tenfold increase of AUC and fourfold prolonged elimination half-life — a clinically significant pharmacokinetic interaction that substantially raises exposure and thus adverse effect risk.

Understanding a patient's CYP2D6 metabolic activity and phenotyping patients for CYP2D6 activity before initiating yohimbine treatment might be crucial for determining safe doses and minimizing overdose risk.

7.5 Supplement Labeling and Variability Concerns

Substances purported to be extracts from the yohimbe tree have been marketed as dietary supplements for various purposes, especially for erectile dysfunction, but they contain highly variable amounts of yohimbine, if any; no published clinical evidence supports the efficacy of yohimbe bark extract products for treating sexual dysfunction or any disease. Some of the yohimbine in products was either synthetic or from highly processed plant extracts. Most of the supplements did not provide information about known side effects.

Yohimbe- and yohimbine-containing dietary supplement products may contain varying amounts of yohimbine. Yohimbe and yohimbine in dietary supplements have been associated with severe adverse events. They may harm a Service Member's health and readiness for duty.

References

• Nowacka A, et al. "Multifaced Nature of Yohimbine—A Promising Therapeutic Potential or a Risk?" International Journal of Molecular Sciences. 2024;25(23):12856. PMC.
• ScienceDirect Topics: Pausinystalia — Pharmacology, Toxicology and Pharmaceutical Science Overview
• ScienceDirect Topics: Yohimbine — Chemistry Overview
• Wikipedia: Corynanthe johimbe
• Wikipedia: Yohimbine
• European Commission Food Safety: Scientific Assessment of Yohimbe (Pausinystalia yohimbe)
• NIH National Center for Complementary and Integrative Health (NCCIH): Yohimbe — Usefulness and Safety
• Operation Supplement Safety (OPSS / U.S. Department of Defense): Yohimbe and Yohimbine in Dietary Supplement Products
• Ernst E, Pittler MH. "Yohimbine for Erectile Dysfunction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials." Journal of Urology. 1998;159(2):433–436.
• Ernst E, Pittler MH. "Yohimbine for Erectile Dysfunction: A Systematic Review and Meta-Analysis." In: Database of Abstracts of Reviews of Effects (DARE). NCBI Bookshelf.
• Wibowo DNSA, Soebadi DM, Soebadi MA. "Yohimbine as a Treatment for Erectile Dysfunction: A Systematic Review and Meta-Analysis." Turk J Urol. 2021.
• Kucio C, et al. "Does Yohimbine Act as a Slimming Drug?" PubMed. Isr J Med Sci. 1991.
• Berlin I, et al. "[Lack of Efficacy of Yohimbine in the Treatment of Obesity]." PubMed. J Pharmacol. 1986.
• Galitzky J, et al. "Alpha 2-Antagonist Compounds and Lipid Mobilization: Evidence for a Lipid Mobilizing Effect of Oral Yohimbine in Healthy Male Volunteers." PubMed. Eur J Clin Invest. 1988.
• Lafontan M, et al. "The Alpha 2-Adrenergic Receptor Antagonist Yohimbine Inhibits Epinephrine-Induced Platelet Aggregation in Healthy Subjects." PubMed. Clin Pharmacol Ther. 1991.
• Goldberg MR, et al. "The Pharmacokinetics of Yohimbine in Man." PubMed. Eur J Clin Pharmacol. 1988.
• Nowacka A, et al. "Multifaced Nature of Yohimbine—A Promising Therapeutic Potential or a Risk?" MDPI International Journal of Molecular Sciences. 2024.
• Vay M, et al. "CYP2D6 Phenotype Explains Reported Yohimbine Concentrations in Four Severe Acute Intoxications." PMC / Clin Pharmacokinetics. 2021.
• Vay M, et al. "Oral Yohimbine as a New Probe Drug to Predict CYP2D6 Activity: Results of a Fixed-Sequence Phase I Trial." PMC / Clin Pharmacokinetics. 2020.
• Vay M, et al. "Simultaneous Quantification of the CYP2D6 Substrate Yohimbine, Its Metabolite 11-OH-Yohimbine, and the CYP2D6 Inhibitor Paroxetine in Human Plasma." RSC Analytical Methods. 2019.
• Al-Khayri JM, et al. "A Literature Perspective on the Pharmacological Applications of Yohimbine." PMC / Molecules. 2022.
• Severe Acute Intoxication with Yohimbine: Four Simultaneous Poisoning Cases. Forensic Science International. 2021.
• Kearney T, Tu N, Haller C. "Adverse Drug Events Associated with Yohimbine-Containing Products: A Retrospective Review of the California Poison Control System Reported Cases." Ann Pharmacother. 2010.
• Narrative Review: The FDA's Perfunctory Approach of Dietary Supplement Regulations Giving Rise to Copious Reports of Adverse Events. PMC. 2023.
• Powers MB, et al. "Yohimbine Enhancement of Exposure Therapy for Social Anxiety Disorder: A Randomized Controlled Trial." Biological Psychiatry. 2014.
• Dalley JW, et al. "The Pharmacological Stressor Yohimbine Increases Impulsivity through Activation of CREB in the Orbitofrontal Cortex." PMC / Neuropsychopharmacology. 2010.
• Effects of Dietary Supplements on Athletic Performance in Elite Soccer Players: A Systematic Review. PMC / Journal of the International Society of Sports Nutrition. 2023.
• Ostojic SM. "Yohimbine: The Effects on Body Composition and Exercise Performance in Soccer Players." Research in Sports Medicine. 2006.
• Iciek M, et al. "Yohimbine Alleviates Oxidative Stress and Suppresses Aerobic Cysteine Metabolism Elevated in the Rat Liver of High-Fat Diet-Fed Rats." PMC / Molecules. 2023.
• Yohimbine-Induced Reactivity of Heart Rate Variability in Unmedicated Depressed Patients. PMC / Frontiers in Psychiatry. 2022.
• PeaceHealth Health Library: Yohimbe